TY - JOUR
KW - Antiretroviral Therapy, Highly Active/economics
KW - Buprenorphine/economics/therapeutic use
KW - Delivery of Health Care, Integrated/economics/methods
KW - Female
KW - Financing, Government
KW - Health Care Costs
KW - Health Policy
KW - Health Resources
KW - HIV Infections/diagnosis/drug therapy/economics
KW - Humans
KW - Insurance, Health, Reimbursement/economics
KW - Male
KW - Narcotic Antagonists/economics/therapeutic use
KW - Opioid-Related Disorders/diagnosis/drug therapy/economics
KW - Primary Health Care/economics
KW - Quality of Health Care
KW - United States
AU - B. R. Schackman
AU - J. O. Merrill
AU - D. McCarty
AU - J. Levi
AU - C. Lubinski
A1 - 
AB - Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.
BT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
C5 - Financing & Sustainability; HIT & Telehealth; Healthcare Policy
CY - United States
DO - 10.1086/508190
JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
N2 - Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.
PP - United States
PY - 2006
SN - 1537-6591; 1058-4838
EP - 53
EP - S247+
T1 - Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care
T2 - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
TI - Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care
U1 - Financing & Sustainability; HIT & Telehealth; Healthcare Policy
U2 - 17109311
U3 - 10.1086/508190
VL - 43 Suppl 4
VO - 1537-6591; 1058-4838
Y1 - 2006
ER -